UnitedHealth Group faces DOJ criminal probe amid stock turmoil. Will the gaps be filled? (and most importantly when)
This situation shows the critical importance of compliance and transparency in the healthcare industry, especially for companies managing public funds.
UnitedHealth Group is under a criminal investigation by the U.S. Department of Justice for potential Medicare fraud, as reported by the Wall Street Journal. This follows a civil inquiry earlier this year and a separate Senate investigation into the company's Medicare billing practices.
The company's stock has experienced significant volatility, recently closing at $308.01, marking a 48% decline over the past month and a 40% drop year-over-year. Analysts have adjusted their outlooks accordingly, with Oppenheimer setting a price target of $400, KeyBanc at $450, and B of A Securities at $350.
#trading #tradingcards #tradingstrategy #daytrading #swingtrading #stocktrading #optionstrading
This situation shows the critical importance of compliance and transparency in the healthcare industry, especially for companies managing public funds.
UnitedHealth Group is under a criminal investigation by the U.S. Department of Justice for potential Medicare fraud, as reported by the Wall Street Journal. This follows a civil inquiry earlier this year and a separate Senate investigation into the company's Medicare billing practices.
The company's stock has experienced significant volatility, recently closing at $308.01, marking a 48% decline over the past month and a 40% drop year-over-year. Analysts have adjusted their outlooks accordingly, with Oppenheimer setting a price target of $400, KeyBanc at $450, and B of A Securities at $350.
#trading #tradingcards #tradingstrategy #daytrading #swingtrading #stocktrading #optionstrading
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.